Polypoidal choroidal vasculopathy in white patients

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE:: To report on a series of white patients in the United States with polypoidal choroidal vasculopathy (PCV). METHODS:: This is a retrospective chart review of 27 patients at a single center with PCV. RESULTS:: The mean age was 74.3 with 48% being male. The most common presenting diagnosis was exudative age-related macular degeneration in 59%, and it took 17.5 months to diagnose PCV. During this time, patients received one antivascular endothelial growth factor injection every 1.3 months. The most common reason for suspecting PCV was a large retinal pigment epithelial detachment or a poor response to antivascular endothelial growth factor therapy. Once PCV was diagnosed, most underwent photodynamic therapy. In those who received photodynamic therapy, the fluid and/or age-related macular degeneration decreased in 86%. The vision improved in 41% with 36% maintaining stable vision. Patients received only one additional injection every 3.95 months after photodynamic therapy. CONCLUSION:: This is one of the larger series of PCV in an entirely white population. It emphasizes the importance of diagnosis in whites as PCV can masquerade as recalcitrant exudative age-related macular degeneration. Common findings were a temporal or peripapillary location and the presence of lipid. After photodynamic therapy, the patients still required antivascular endothelial growth factor therapy, but the injection burden was decreased by 67% and vision was found to be improved or maintained in 77% of patients.

Original languageEnglish (US)
Pages (from-to)2185-2191
Number of pages7
JournalRetina
Volume34
Issue number11
DOIs
StatePublished - Nov 12 2014

Fingerprint

Endothelial Growth Factors
Photochemotherapy
Macular Degeneration
Injections
Retinal Detachment
Lipids
Therapeutics
Population

Keywords

  • age-related macular degeneration
  • avastin
  • bevacizumab
  • indocyanine green
  • photodynamic therapy
  • pigment epithelial detachment
  • ranibizumab
  • white

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Polypoidal choroidal vasculopathy in white patients. / Davis, Stephen; Lauer, Andreas (Andy); Flaxel, Christina.

In: Retina, Vol. 34, No. 11, 12.11.2014, p. 2185-2191.

Research output: Contribution to journalArticle

@article{48d3ff05470646bcaa81aaf71a2b2fc2,
title = "Polypoidal choroidal vasculopathy in white patients",
abstract = "PURPOSE:: To report on a series of white patients in the United States with polypoidal choroidal vasculopathy (PCV). METHODS:: This is a retrospective chart review of 27 patients at a single center with PCV. RESULTS:: The mean age was 74.3 with 48{\%} being male. The most common presenting diagnosis was exudative age-related macular degeneration in 59{\%}, and it took 17.5 months to diagnose PCV. During this time, patients received one antivascular endothelial growth factor injection every 1.3 months. The most common reason for suspecting PCV was a large retinal pigment epithelial detachment or a poor response to antivascular endothelial growth factor therapy. Once PCV was diagnosed, most underwent photodynamic therapy. In those who received photodynamic therapy, the fluid and/or age-related macular degeneration decreased in 86{\%}. The vision improved in 41{\%} with 36{\%} maintaining stable vision. Patients received only one additional injection every 3.95 months after photodynamic therapy. CONCLUSION:: This is one of the larger series of PCV in an entirely white population. It emphasizes the importance of diagnosis in whites as PCV can masquerade as recalcitrant exudative age-related macular degeneration. Common findings were a temporal or peripapillary location and the presence of lipid. After photodynamic therapy, the patients still required antivascular endothelial growth factor therapy, but the injection burden was decreased by 67{\%} and vision was found to be improved or maintained in 77{\%} of patients.",
keywords = "age-related macular degeneration, avastin, bevacizumab, indocyanine green, photodynamic therapy, pigment epithelial detachment, ranibizumab, white",
author = "Stephen Davis and Lauer, {Andreas (Andy)} and Christina Flaxel",
year = "2014",
month = "11",
day = "12",
doi = "10.1097/IAE.0000000000000206",
language = "English (US)",
volume = "34",
pages = "2185--2191",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Polypoidal choroidal vasculopathy in white patients

AU - Davis, Stephen

AU - Lauer, Andreas (Andy)

AU - Flaxel, Christina

PY - 2014/11/12

Y1 - 2014/11/12

N2 - PURPOSE:: To report on a series of white patients in the United States with polypoidal choroidal vasculopathy (PCV). METHODS:: This is a retrospective chart review of 27 patients at a single center with PCV. RESULTS:: The mean age was 74.3 with 48% being male. The most common presenting diagnosis was exudative age-related macular degeneration in 59%, and it took 17.5 months to diagnose PCV. During this time, patients received one antivascular endothelial growth factor injection every 1.3 months. The most common reason for suspecting PCV was a large retinal pigment epithelial detachment or a poor response to antivascular endothelial growth factor therapy. Once PCV was diagnosed, most underwent photodynamic therapy. In those who received photodynamic therapy, the fluid and/or age-related macular degeneration decreased in 86%. The vision improved in 41% with 36% maintaining stable vision. Patients received only one additional injection every 3.95 months after photodynamic therapy. CONCLUSION:: This is one of the larger series of PCV in an entirely white population. It emphasizes the importance of diagnosis in whites as PCV can masquerade as recalcitrant exudative age-related macular degeneration. Common findings were a temporal or peripapillary location and the presence of lipid. After photodynamic therapy, the patients still required antivascular endothelial growth factor therapy, but the injection burden was decreased by 67% and vision was found to be improved or maintained in 77% of patients.

AB - PURPOSE:: To report on a series of white patients in the United States with polypoidal choroidal vasculopathy (PCV). METHODS:: This is a retrospective chart review of 27 patients at a single center with PCV. RESULTS:: The mean age was 74.3 with 48% being male. The most common presenting diagnosis was exudative age-related macular degeneration in 59%, and it took 17.5 months to diagnose PCV. During this time, patients received one antivascular endothelial growth factor injection every 1.3 months. The most common reason for suspecting PCV was a large retinal pigment epithelial detachment or a poor response to antivascular endothelial growth factor therapy. Once PCV was diagnosed, most underwent photodynamic therapy. In those who received photodynamic therapy, the fluid and/or age-related macular degeneration decreased in 86%. The vision improved in 41% with 36% maintaining stable vision. Patients received only one additional injection every 3.95 months after photodynamic therapy. CONCLUSION:: This is one of the larger series of PCV in an entirely white population. It emphasizes the importance of diagnosis in whites as PCV can masquerade as recalcitrant exudative age-related macular degeneration. Common findings were a temporal or peripapillary location and the presence of lipid. After photodynamic therapy, the patients still required antivascular endothelial growth factor therapy, but the injection burden was decreased by 67% and vision was found to be improved or maintained in 77% of patients.

KW - age-related macular degeneration

KW - avastin

KW - bevacizumab

KW - indocyanine green

KW - photodynamic therapy

KW - pigment epithelial detachment

KW - ranibizumab

KW - white

UR - http://www.scopus.com/inward/record.url?scp=84926475202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926475202&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000206

DO - 10.1097/IAE.0000000000000206

M3 - Article

VL - 34

SP - 2185

EP - 2191

JO - Retina

JF - Retina

SN - 0275-004X

IS - 11

ER -